Find an expert

Dr. Albornoz is an early career researcher who has training in neuroscience, immunology, and pharmacology. Prior to migrating to Australia, he completed a bachelor's in Biochemistry followed by a master’s degree in Chile, he then gained experience working in Chile as a research assistant in the Millennium Institute for Immunology and Immunotherapy, focusing on neurodegeneration and the immune response in the context of Multiple Sclerosis. Later, he was awarded a UQ international scholarship to undertake a Ph.D. at the Institute for Molecular Biosciences (IMB), under the supervision of Prof Matt Cooper, his Ph.D. project has assisted in the development of next-generation NLRP3 inflammasome inhibitors, and to validate NLRP3 as a druggable therapeutic target for Parkinson’s disease. He completed his Ph.D. in 2019 and continued his post-doctoral research studies under the supervision of Prof Trent Woodruff. A key focus of his current work is testing novel drugs in preclinical models and understanding the role of the peripheral innate immune response in neurodegenerative diseases including motor neuron disease (amyotrophic lateral sclerosis), Huntington's disease, and Parkinson's disease.

Prof. Derek Arnold

Prof. Arnold studied at Macquarie University before taking up research positions at the University of Sydney and University College London. He took up a continuing position at the University of Queensland in April, 2006.

Dr. Awais Saleem Babri is a dedicated educator and researcher in biomedical sciences, specializing in innovative anatomy education, curriculum development, and technology-enhanced learning. With over two decades of experience at The University of Queensland, his work focuses on integrating virtual reality (VR), digital repositories, and evidence-based pedagogies to transform medical and health professions education.

Key Contributions:

• Teaching Excellence: Led curriculum reviews and course coordination for programs in medicine, nursing, and paramedicine, enhancing clinical integration and student engagement. Recognized with multiple awards, including the UQ Citation for Excellence in Teaching (2009) and nominations for national teaching honors.

• Research Leadership: Secured over $105K in grants to pioneer VR classrooms and image repositories, improving accessibility and outcomes in anatomy education. Presented at 15+ international conferences, including IFAA and ANZAHPE, with pending publications on VR and ward-round pedagogy.

• Supervision & Mentorship: Guided honours and summer research students, with projects on surgical simulation and ward-round pedagogy earning scholarships and conference presentations (e.g., ANZACA 2024, ANZAHPE 2025).

• Leadership & Service: Founded the Gross Anatomy Evaluations Network (GAEN), uniting 28 universities to standardize assessments. Served as ANZACA Vice President (2025–present) and contributed to committees (UQ HREC, ANZAHPE DEI).

Dr. Babri’s work bridges cutting-edge technology and pedagogical innovation, making him a sought-after collaborator in health professions education. For details on projects or partnerships, contact a.babri@uq.edu.au.

Dr Bademosi received his BSc(Hons) in Medical Physiology from the University of Lagos (Nigeria) in 2010, and his MSc and PhD in Neuroscience from the Queensland Brain Institute at the University of Queensland in 2014 and 2018 respectively. He pioneered super-resolution single-molecule microscopy in vivo during his PhD, where he examined nanoscale changes in synaptic proteins during neurotransmission and under general anaesthesia. In 2018, obtained the highly competitive European Molecular Biology Organisation (EMBO) postdoctoral fellowship.to carry out his postdoctoral training in the lab of Professor Patrik Verstreken who is the current Director of of the Centre for Brain and Disease Research, Flemish Institute of Biotechnology, KU Leuven, Belgium. Here, he characterised how disease coding variants in risk genes for Parkinson's Disease elicit onset of neuronal degeneration (published in Neuron). Dr Bademosi was awarded the inaugural Race Against Dementia - Dementia Australia Research Foundation postdoctoral fellowship in 2020, to carry examine advanced nanoscale investigation into changes in the organisation and dynamics of the Motor Neuron Disease and Frontotemporal Dementia linked protein TDP-43. His research has been supported by grants from the Brain Foundation Australia, Dementia Australia Research Foundation, Motor Neuron Disease Research Institute of Australia, and the Australian Research Council.

I am an academic paediatric neurologist, clinical researcher, and specialist in acquired brain injury in children and adolescence. I studied at the University of Edinburgh and British Columbia before taking up my first academic position at the University of Calgary in 2002. Here I developed and directed the Traumatic Brain Injury and Concussion Research Program at the Alberta Children's Hospital and where I cemented my interest in the biology and treatment of children with brain injuries. I have extensive clinical research experience, devising and overseeing clinical trials in children both nationally and internationally. I moved to the Child Health Research Centre at the University of Queensland, Australia in October 2017 and joined the Queensland Paediatric Rehabilitation Service and Queensland Cerebral Palsy Rehabililation Centre to facilitate research into improving the health outcomes of children with acquired brain injury in Queensland and Australia.

My research focuses on the neurobiological signatures and treatment of subtle neurological dysfunction in mild traumatic brain injury and concussion, especially the behavioural and cognitive impairments that are found in post-concussion syndrome. I use multimodal neurological assessments to do this. My research explores combining neuroimaging and neurophysiological investigations, including perfusion studies using MRI (ASL-fMRI) and transcranial magnetic stimulation to help us understand the changes in the brain in children who are slow to recovery following a concussion. This is to help us develop and assess more effective and tailored treatments for children with concussion and traumatic brain injury. I explore novel therapies for children with persistent post-concussive symptoms in clinical trials including the use of neuraceuticals, pharmacotherapies, and non-invasive brain stimulation treatment.

I am the director of the newly-established KidStim Lab at the Child Health Research Centre. This is the first non-invasive neuromodulation facility aimed at improving the health outcomes of children with brain injury in Australia and is led by a mulitdisciplinary team of clinicians and scientists from Brisbane bring a unique clinical and scientific knowledge-base to help achieve our goals. Rehabilitation therapy in combination with repetitive transcranial direct current stimulation (rTMS) and other direct current stimulation modalities (e.g. tDCS) will be explored. It also offers the potential for treatment of the mood and behavioural disorders (e.g. depression and anxiety) commonly seen after brain injury but also so disruptive to the life of the normally developing teenager.

Dr Ben Barry is an allied health professional working clinically in aged care with Wesley Mission Queensland.

Dr Barry has a research background in adaptations of the nervous system to exercise and ageing. His research interests have progressed to health professional education, spanning digital health, interprofessional education and workforce development. Dr Barry's clinical work as a physiotherapist and exercise physiologist with a focus on healthy ageing links nicely with his PhD thesis on "Resistance training and movement control in older adults".

Dr Barry has extensive experience teaching allied health (exercise physiology), medical science and medical students. This has included coordinating degree programs and courses, leading teaching teams and discipline-wide curriculum reviews, expanding and enhancing clinical placement programs and student clinics, and innovations in online teaching of health professionals.

Dr Barry completed postdoctoral training in the Neurophysiology of Movement Laboratory at the Department of Integrative Physiology, the University of Colorado - Boulder USA, and subsequently worked for a decade at the School of Medical Sciences, The University of New South Wales, as well as holding an honorary appointment at Neuroscience Research Australia, before returning to The University of Queensland in 2017. He has a track record of external research funding and postgraduate research supervision as well as several teaching awards.

Markus graduated from the Vienna University of Technology in Technical Physics in 1995 and was awarded his Doctorate in 1999 after which he worked as postdoctoral research associate and then Assistant Professor at the Department of Radiodiagnostics, Medical University Vienna (AT). From 2004 he worked as Senior Researcher at the Donders Institute for Brain, Cognition and Behaviour (Radboud University Nijmegen, NL) and at the Erwin L. Hahn Institute for Magnetic Resonance Imaging (University Essen-Duisburg, DE). In 2014 he relocated to the University of Queensland to head the Ultra-high Field Human MR Research program at the Centre for Advanced Imaging and was awarded an ARC Future Fellowship. In 2019 he joined the School of Information Technology and Electrical Engineering as Full Professor Biomedical Engineering working on MR Physics and Medical Imaging. He served as Imaging, Sensing and Biomedical Engineering Discipline lead until 2020 when he took up service roles as Deputy Head of School – Research, Director for the National Imaging Facility – Queensland Node, as well as a member of the ARC College of Experts.

Dr Lizzie Beadle is a clinical psychologist, neuropsychologist, and researcher. Her research is focused on neuropsychological rehabilitation, changes to self-awareness and identity after brain injury, and use of technology in rehabilitation. She has practiced as a psychologist from acute through to community services. She is experienced in translation of research in to clinical practice. She is passionate about supporting a lifelong love of learning in students and clinicians. She is also passionate about supporting greater medical and lifestyle choice and control for individuals with disabilities.

Stefanie was awarded a PhD in Cognitive Psychology / Experimental Psychology in 2007, from the University of Bielefeld, Germany, and was subsequently awarded two awards for it (amongst them the National German Dissertation Award). She then took up a 1-year post-doc position with Prof Roger Remington at UQ. Subsequently, her work was supported by various fellowships from UQ and the ARC, allowing Stefanie to focus mainly on research from 2009 - 2018. Afterwards she was employed on a Teaching and Research position at UQ, where she is currently employed as an Associate Professor.

Personal website: www.sibecker.com

Electrophysiology of synaptic transmission, ion currents and central pattern generation in CNS neurones.

Current research focuses on the electrophysiology of central nervous system neurones using various in vitro slice and in vivo preparations, patch clamp techniques, imaging, molecular biology and computer modelling.

Projects include :

• Neurobiology of motor control
• Motor neuron disease
• Synaptic transmission in the cochlear nucleus
• Potassium currents in the brainstem and cerebellum
• Rhythmic control of breathing movements

Stefan is a Staff Specialist in Neurology at the Princess Alexandra Hospital (PAH) and the Mater Centre for Neuroscience. He finished his training as neurologist in 2012.

He runs dedicated multiple sclerosis (MS) and Neuroimmunology clinics at the PAH, leading in modern MS therapies. Moreover, he has been at the forefront of advancing the field of neuroimmunology in Queensland, with establishment of dedicated neuroimmunology outpatient clinics at the RBWH and PAH, combining expertise from neurologists and immunologists in the care of this very complex group of disorders.

In addition to his busy, full-time clinical workload, Stefan has been involved as PI or CI in a range of clinical trials in the fields of MS, botulinum toxin, CIDP and Pompe’s disease. Additionally, he has performed and is involved in ongoing research projects of neuroimmunological disorders such as neuromyelitis optica, myasthenia gravis and autoimmune limbic encephalitis. He has been a member of the New Horizons study to assess prevalence of anti-neuronal antibodies in patients with new onset psychosis.

Prior to this, Stefan finished a PhD in the field of ‘Immunogenetics of Guillain-Barre Syndrome and Chronic inflammatory polyneuropathy’ at the University of Queensland in 2014. He also completed a doctoral thesis at the University of Heidelberg, Germany in 2002 in the field of T cell immunology. During this time, he has developed solid skills in bench-side immunological research.

Currently, he is neurological lead in a diverse group of clinicians and scientists investigating the role of antineuronal antibodies in neurological and psychiatric disease. He supervises 3 PhD students in the field of advanced imaging in autoimmune encephalitis and multiple sclerosis. He is currently building up a laboratory to test antineuronal antibodies using live cell assays.

Dr Steffen Bollmann joined UQ’s School of Electrical Imaging and Computer Science in 2020 where he leads the Computational Imaging Group. The Group is developing computational methods to extract clinical and biological insights from magnetic resonance imaging (MRI) data. The aim is to make cutting-edge algorithms and tools available to a wide range of clinicians and researchers. This will enable better images, faster reconstruction times and the efficient extraction of clinical information to ensure a better understanding of a range of diseases. Dr Bollmann was appointed Artificial Intelligence (AI) lead for imaging at UQ’s Queensland Digital Health Centre (QDHeC) in 2023.

His research expertise is in quantitative susceptibility mapping, image segmentation and software applications to help researchers and clinicians access data and algorithms.

Dr Bollmann completed his PhD on multimodal imaging at the University Children’s Hospital and Swiss Federal Institute of Technology (ETH) Zurich, Switzerland.

In 2014 he joined the Centre for Advanced Imaging at UQ as a National Imaging Facility Fellow, where he pioneered the application of deep learning methods for quantitative imaging techniques, in particular Quantitative Susceptibility Mapping.

In 2019 he joined the Siemens Healthineers collaborations team at the MGH Martinos Center in Boston on a one-year industry exchange where he worked on the translation of fast imaging techniques into clinical applications.

At the age of 15 I thought that I would like to develop new treatments for diseases where there is a need. After studying Biology in Germany and while working as a post-doctoral fellow with Professor Raymond Dingledine at Emory University, I became passionate about epilepsy. When starting my own laboratory at Texas Tech University, I began to investigate impairments in energy metabolism in epilepsy and potential new treatments to address energetic deficiencies. In 2011, I moved to UQ and have since enjoyed the many opportunities working with many talented students and professionals and within the globally highly respected Australin epilepsy community.

Recent research:

Among many other projects, my lab has characterized several metabolic alterations and impairments in energy metabolism in epilepsy (1, 2) and Motor Neuron Disease (1). In brain areas that can generate seizures, cytosolic and mitochondrial metabolism of glucose is impaired (1), which can lead to energy deficits and may trigger seizures. From a biochemical standpoint, auxiliary fuels such as ketone bodies and medium chain fatty acids derived from medium chain triglyceride (MCTs) are well suited to improve energy levels. We have also shown that different MCTs, including triheptanoin, when added to normal diets can prevent seizure generation in seizure models (reviewed here 1, 2) and prevent motor neuron death in an MND model (1).

Our latest research aims to increase glucose transport into brain cells for glucose transporter 1 deficiency and epilepsy.

Research in the Bredy laboratory is aimed at elucidating how the genome is connected to the environment through epigenetic modifications, and how this relationship shapes brain and behaviour throughout life. The group is particularly interested in how epigenetic mechanisms, including DNA methylation, histone modifications. the activity of non-coding RNAs, and RNA modification regulate the formation and maintenance of associative fear-related memory.

Professor Burne is a leading Australian researcher in the field of biological psychiatry. Prof. Burne has >150 peer reviewed publications, which have attracted over 8500 citations (H-index 50). His research impact is evident by his 11 papers with >200 citations, with two recognised as Web of Science ‘Highly Cited Papers’. Together with collaborators he has been awarded >$8 million in research funding. Since 2003 he has supervised 17 PhD students, and 28 honours students Prof. Burne has a broad background in behavioural neuroscience, with specific training and expertise in animal models. As a Professorial Research Fellow with the Queensland Centre for Mental Health Research and Group Leader at the Queensland Brain Institute (QBI) the focus of his research includes cognitive testing in rodent models of neuropsychiatric disorders, such as schizophrenia, as well as psychopharmacological studies and research on clinical populations. As a CI on several university- and NHMRC-funded grants, he has helped establish infrastructure at QBI for behavioural assessment and methods of automated operant-based cognitive tests in rodents. Prof. Burne is a past president of Biological Psychiatry Australia, he is the Queensland representative for the Australasian Neuroscience Society, and he is a member of the NHMRC Animal Welfare Committee.

Prof. Burne’s group studies brain development and behaviour in animal models to learn more about neuropsychiatric diseases, such as schizophrenia. Research is focused on investigating the underlying biological basis for schizophrenia, with the goal of finding public health interventions that will alleviate the burden of this disease. The group has been exploring the impact of developmental vitamin D (DVD) deficiency on brain development, the impact of adult vitamin D deficiency on brain function and behaviour, and the neurobiological affects of having an older father. More recently his group has been focussed on assessing cognitive function in rodents. Prof. Burne’s research is carried out in close collaboration with Professors John McGrath and Darryl Eyles, in a multidisciplinary team. Together they have an integrated research program using a broad range of neuroscientific techniques to explore potential causes of schizophrenia. There is a particular focus on early life, nongenetic risk factors and the team has skills in epidemiology, psychiatry, neuroanatomy, molecular biology, developmental biology and behavioural neuroscience. The Burne group is currently developing animal models related to risk factors for schizophrenia and autism.

Researching venom peptides and ion channel pharmacology to develop next-generation therapeutics for neurological disorders

Dr Fernanda Cardoso is a Brazil-born Australian dual-citizen researcher interested in venom peptide-based biodiscovery and therapeutics development. Cardoso was awarded an MSc in Molecular Pharmacology and a PhD with an emphasis in Biochemistry and Immunology and is part of the Institute for Molecular Bioscience, where she develops novel therapies for complex neurological diseases. Cardoso has interdisciplinary training in the fields of neuropharmacology, medicinal chemistry and chemical biology and a strong background in drug discovery, which provides the skills to identify naturally occurring or synthetic bioactive molecules and to study their effects in human physiology with applications in neurologic disorders such as chronic pain, irritable bowel syndrome (IBS), and motor neuron disease (MND). Please see Dr Cardoso’s Grants and Publications list for more details.

Before joining the University of Queensland, Dr Cardoso was part of the Queensland Institute for Medical Research, holding a prestigious CAPES Postdoctoral Fellowship. During this period, Cardoso developed unique high-throughput screen platforms for discovering protein and peptide targets of novel therapies to combat infectious diseases and novel helminth-derived bioactives with anti-inflammatory properties. Please see Dr Cardoso’s Publications list for more details.

Dr Cardoso is currently part of the Centre for Drug Discovery and manages several industry and academic projects studying ion channel modulators derived from natural repertoires, particularly venoms, and developing novel, effective drugs to treat neurological disorders.

Dr Carroll completed his doctorate in Neuroscience at the University of Queensland in 2001. He was awarded an Isaac Walton Killam Memorial Scholarship to pursue postdoctoral studies at the University of Alberta in 2002, before accepting a position as a Lecturer in Human Motor Control at the University of New South Wales in 2003. He joined the School of Human Movement Studies as a Senior Lecturer in July 2007.

Dr Carroll’s research interests lie in the broad field of integrative human physiology. His work spans the fields of exercise science and integrative neuroscience, with a focus on determining how the central nervous system is reorganised as a consequence of motor learning and exercise. He has a specific interest in the area of strength training. Dr Carroll’s research involves the application of electro-physiological techniques such as Transcranial Magnetic Stimulation (TMS), peripheral nerve stimulation, and electromyography (EMG) in experiments involving human subjects. The ultimate purpose of his work is to generate basic knowledge that will lead to the development of exercise protocols that yield maximal benefits for rehabilitation and injury prevention. His work has been funded by the Australian Research Council (ARC) since 2004.

Dr Kirat Chand is a Research Fellow at the Perinatal Research Centre at The University of Queensland Centre for Clinical Research (UQCCR). His field of expertise include the establishment of synaptic connections, neurodevelopment and cellular changes associated with injury in the neonatal brain. His current work investigates the evolution of brain injury in fetal growth restricted newborns (FGR) with a particular interest in understanding mechanisms to develop better detection and treatment strategies for FGR newborns. FGR is the second leading cause of perinatal morbidity and mortality, with around 32 million babies born FGR globally each year. FGR is commonly caused by placental insufficiency, resulting in an inadequate supply of oxygen and nutrients to the foetus. The brain is particularly vulnerable to FGR conditions and adverse outcomes in these children range from mild learning difficulties, to neurobehavioral issues, and in some cases cerebral palsy. Currently there are no interventions available to protect the FGR brain. Using the pre-clinical pig model of FGR, we are able to examine perturbations to white and grey matter regions of the newborn brain, with the aim of developing appropriate therapeutic strategies to aid this vulnerable population.

• My academic qualifications include a PhD in Neurosciences, an MSc in Biochemistry and Molecular Biology, and a Bachelor of Medicine.
• I have initiated and managed multiple projects to develop novel therapeutics for neurological disorders, including: 1) Developing a nanoparticle-based siRNA delivery system for the treatment of Huntington’s disease (ARC project; as Postdoctoral Research Fellow). 2) Examining the treatment effects of intravenous immunoglobulin (IVIg) on epilepsy (Advance Queensland Women’s Academic Fund; as Sole Investigator). 2) Examining the effectiveness of three neuroinflammation modulatory agents on traumatic brain injury and epilepsy through randomised controlled preclinical trials (Seed projects sponsored by industry partners: VivaZome Therapeutics, Implicit Bioscience, and Innate Immunotherapeutics; as Co-investigator). 3) Developing treatment strategies to prevent the development of epilepsy after severe traumatic brain injury and identifying medical imaging biomarkers to evaluate the risk of epilepsy post-injury (two U.S. Department of Defense, Congressionally Directed Medical Research Programs; as Co-investigator). 4) Developing exosomal therapy for traumatic brain injury (Cooperative Research Centres Projects (CRC-P) Grant with two research groups from academic institutions and three pharmaceutical companies; as Principal Investigator).